Price | $17.57 |
---|---|
netCurrentAssetsPerShare | $-1.64 |
netTangibleAssetsPerShare | $0.59 |
maxEarningPowerPerShare | $2.87 |
adjustedEarningPower |
$0.41
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
nonCashChargeToMKTCAP |
1.83%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
cashValuePerShare | $0 |
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.